Acetylated pentapeptide with anti-inflammatory effect and application thereof
By extracting and modifying acetylated pentapeptide from Yunnan crocodile flower plants, combining lotus seeds and Schisandra extracts to form an anti-inflammatory composition, the problem of lack of effective anti-inflammatory peptides in the prior art was solved, and NF-κB was achieved The inhibition of /NLRP3 signaling pathway and significant reduction in inflammatory response have broad application prospects.
Patent Information
- Application Number
- CN202411233478.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-12-10
AI Technical Summary
There is a lack of effective anti-inflammatory peptides in the prior art, especially for the treatment of inflammatory skin diseases, and there are relatively few anti-inflammatory peptides available, which cannot effectively inhibit the activity of NLRP3 and NF-κB, resulting in the occurrence of excessive inflammatory response.
Acetylated pentapeptide was extracted from Yunnan crocodile leukoba flower plants, and the polypeptide sequence WDDC with anti-inflammatory potential was obtained through LC MS/MS identification and computer virtual screening, and acetylation modification and glycine introduction were performed to prepare acetylated with anti-inflammatory effects. The pentapeptide is combined with lotus seed extract and Schisandra extract to form a synergistic anti-inflammatory composition.
Acetylated pentapeptide can target the NF-κB/NLRP3 signaling pathway, inhibit the expression of TLR4 factor, reduce the expression of NO, TNF-α and IL-6, significantly inhibit the inflammatory response, and when combined with lotus seed extract and Schisandra extract, Enhances anti-inflammatory effects and is suitable for food, cosmetics and health products.
Smart Images
Figure CN119101124A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of bioactive peptides, in particular to an acetylated pentapeptide with anti-inflammatory effect and application thereof. Background Art
[0002] In recent years, active ingredients derived from plants have been increasingly used in products such as food, cosmetics and health products.
[0003] Peptides play an important role in the growth, development and metabolism of organisms, and also play a key regulatory role in the natural aging and care of the skin. Inflammation, aging, wrinkles and dullness of human skin are caused by a variety of internal and external factors. The more popular commercial peptides on the market are mostly anti-wrinkle and anti-aging peptides, such as acetyl hexapeptide-3 (Argirelin), palmitoyl tripeptide-5 and palmitoyl pentapeptide-3, as well as whitening peptides such as tetrapeptide-30 and nonapeptide-1, while anti-inflammatory peptides are relatively rare.
[0004] Inflammation is a stress response produced by the human body after adverse stimulation. Excessive inflammatory response may cause long-term tissue damage and eventually lead to the occurrence of acute or chronic inflammatory diseases. Inflammasomes are an important component of the innate immune system's response to pathogens. Among various inflammasome subtypes, Nod-like receptor protein 3 (NLRP3) is associated with a variety of inflammatory or autoimmune skin diseases, such as tinea, psoriasis, acne, and urticaria. When external danger signals such as lipopolysaccharide (LPS) or Toll-like receptor 4 (TLR4) are sensed, the NF-κB pathway is activated. Activated NF-κB further upregulates the mRNA transcription levels of NLRP3 and pro-IL-1β. Furthermore, the activated NLRP3 inflammasome can regulate the activation of caspase-1, specifically cleave pro-IL-1β and pro-IL-18, and turn them into activated IL-1β and IL-18, which play a pro-inflammatory role and ultimately initiate the entire inflammatory response. Therefore, studying active substances that effectively inhibit the activation of NLRP3 and NF-κB is of great significance for inhibiting the occurrence and development of excessive inflammatory responses and related diseases.
[0005] Therefore, there is a broad development prospect and urgent need to study and obtain new anti-inflammatory peptides with no toxic side effects from plants. Summary of the invention
[0006] In view of the deficiencies of the prior art, the object of the present invention is to provide an acetylated pentapeptide with anti-inflammatory effect and application thereof.
[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0008] In a first aspect, the present invention provides an acetylated pentapeptide with anti-inflammatory effect, wherein the amino acid sequence of the acetylated pentapeptide with anti-inflammatory effect includes the sequence shown in SEQ ID No. 1, and the N-terminus of the amino acid sequence is acetylated.
[0009] SEQ ID No. 1: WDDCG.
[0010] The pentapeptide sequence of the present invention is derived from a polypeptide extract from the Yunnan crocodile mouth flower plant, which is identified by LC MS / MS, and the physicochemical properties are scored by computer virtual screening (including active peptide scoring websites and peptide toxicity websites) and molecular docking, and finally the polypeptide sequence WDDC with the greatest anti-inflammatory potential is screened out.
[0011] The amino acid sequence shown in SEQ ID No. 1 is not the original amino acid sequence (WDDC) obtained by separation and identification. In order to distinguish it from the human immunoglobulin sequence, a glycine (G) is introduced at the C-terminus of the polypeptide. At the same time, in order to improve the stability of the polypeptide, the N-terminus of the polypeptide sequence is acetylated (Ac). The anti-inflammatory pentapeptide is prepared by solid phase synthesis.
[0012] In a second aspect, the present invention provides a composition with anti-inflammatory effect, comprising the acetylated pentapeptide with anti-inflammatory effect described in the first aspect, lotus seed extract and schisandra chinensis extract.
[0013] The present invention finds that acetylated pentapeptide, lotus seed extract and schisandra chinensis extract have certain synergistic effects in anti-inflammatory effect.
[0014] Preferably, the composition comprises, by mass, 1-2 parts of the acetylated pentapeptide with anti-inflammatory effect described in the first aspect, 1-2 parts of lotus seed extract and 1-2 parts of Schisandra chinensis extract.
[0015] Among them, the specific point values in 1-2 parts can be selected as 1 part, 1.1 parts, 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts, 1.9 parts, 2 parts, etc. Other specific point values within the above numerical range can be selected, and they will not be listed here one by one.
[0016] In a third aspect, the present invention provides a use of the acetylated pentapeptide with anti-inflammatory effect according to the first aspect or the composition with anti-inflammatory effect according to the second aspect in the preparation of a product with anti-inflammatory effect.
[0017] Preferably, the products include food, cosmetics and health products.
[0018] Preferably, the amount of the acetylated pentapeptide with anti-inflammatory effect added to the product with anti-inflammatory effect is 0.01-10%, for example 0.01%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, etc. Other specific point values within the above numerical range can be selected, and they will not be repeated here.
[0019] Preferably, the amount of the composition with anti-inflammatory effect added to the product with anti-inflammatory effect is 0.01-15%, for example 0.01%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, etc. Other specific point values within the above numerical range can be selected, which will not be repeated here.
[0020] In a fourth aspect, the present invention provides a use of the acetylated pentapeptide with anti-inflammatory effect according to the first aspect or the composition with anti-inflammatory effect according to the second aspect in the preparation of an inflammatory factor inhibitor.
[0021] According to the research results of the present invention, acetylated pentapeptides and compositions with anti-inflammatory effects can reduce the expression of inflammatory factors at the cellular level (in vitro level), that is, acetylated pentapeptides and compositions with anti-inflammatory effects can be made into a simple experimental preparation. The inflammatory factor inhibitor claimed by the present invention is not used to eliminate the cause or lesion, that is, it is an application in the preparation of inflammatory factor inhibitors for non-therapeutic purposes.
[0022] Preferably, the inflammatory factors include NO, TNF-α or IL-6.
[0023] In a fifth aspect, the present invention provides a use of the acetylated pentapeptide with anti-inflammatory effect according to the first aspect in the preparation of an inhibitor of the NF-κB signaling pathway.
[0024] According to the research results of the present invention, acetylated pentapeptide can inhibit the expression of factors related to the NF-κB signaling pathway at the cellular level (in vitro level), that is, acetylated pentapeptide can be made into a simple experimental preparation for exploring the physiological metabolic processes related to the NF-κB signaling pathway. The NF-κB signaling pathway inhibitor claimed in the present invention is not used to eliminate the cause or lesion, that is, it is an application in the preparation of NF-κB signaling pathway inhibitors for non-therapeutic purposes.
[0025] In a sixth aspect, the present invention provides a use of the acetylated pentapeptide with anti-inflammatory effect according to the first aspect in the preparation of an inhibitor of the NLRP3 signaling pathway.
[0026] According to the research results of the present invention, acetylated pentapeptide can inhibit the expression of factors related to the NLRP3 signaling pathway at the cellular level (in vitro level), that is, acetylated pentapeptide can be made into a simple experimental preparation for exploring the physiological metabolic processes related to the NLRP3 signaling pathway. The NLRP3 signaling pathway inhibitor claimed in the present invention is not used to eliminate the cause or lesion, that is, it is an application in the preparation of NLRP3 signaling pathway inhibitors for non-therapeutic purposes.
[0027] Compared with the prior art, the present invention has the following beneficial effects:
[0028] (1) The acetylated pentapeptide of the present invention is a new type of small molecule polypeptide, which is connected by only 5 amino acid molecules, has a molecular weight of 637 g / mol, is easy to control in structure, easy to synthesize, has no sensitization and toxicity, and has high application potential.
[0029] (2) The pentapeptide can target the NF-κB / NLRP3 signaling pathway and inhibit the activation of NLRP3 and NF-κB by inhibiting the expression of TLR4 factors, thereby reducing NO production and the expression of inflammatory cytokines TNF-α and IL-6, and inhibiting the inflammatory response.
[0030] (3) The pentapeptide can be combined with lotus seed extract and schisandra chinensis extract to have a good anti-inflammatory effect and exert a synergistic effect.
[0031] (4) The pentapeptide obtained by the present invention can be applied to the fields of food, cosmetics and health care products, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 These are the cytotoxicity test results of WDDC and Ac-WDDCG monomer peptides.
[0033] Figure 2 The effects of WDDC and Ac-WDDCG monomer peptides on NO production, TNF-α and IL-6 expression levels.
[0034] Figure 3A This is the HPLC spectrum of WDDC monomer peptide on day 0.
[0035] Figure 3B This is the HPLC spectrum of WDDC monomer peptide on the 30th day.
[0036] Figure 3C This is the HPLC spectrum of Ac-WDDCG monomer peptide on day 0.
[0037] Figure 3D This is the HPLC spectrum of Ac-WDDCG monomer peptide on the 30th day.
[0038] Figure 4 The inhibitory effect of Ac-WDDCG monomer peptide on the expression of TLR4, NLRP3 and NF-κB factors.
[0039] Figure 5A The effect of Ac-WDDCG monomer peptide on the fluorescence intensity of zebrafish neutrophils.
[0040] Figure 5B Quantitative analysis of the fluorescence intensity of zebrafish neutrophils by Ac-WDDCG monomer peptide. DETAILED DESCRIPTION
[0041] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0042] The extraction method of lotus seed and schisandra chinensis extracts is as follows: grind the prepared raw materials into powder, add purified water according to the solid-liquid ratio of 1g:10mL, ultrasonically extract at 25°C for 30min, the ultrasonic power is 100W, filter the supernatant, filter the supernatant through a 0.14μm ceramic membrane, concentrate at 60°C, and freeze-dry to obtain.
[0043] Example 1 Synthesis and Preparation of Ac-WDDCG Monomer Peptide
[0044] The specific process of solid phase synthesis chemical synthesis is: Fmoc solid phase artificial synthesis is used to prepare a pentapeptide with a sequence of acetyl-tryptophan-aspartic acid-aspartic acid-cysteine-glycine (Ac-Trp-Asp-Asp-Cys-Gly). According to the amino acid residue composition of the pentapeptide, various amino acids (Fmoc-Trp(Boc)-OH, Fmoc-Asp(otbu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gly-OH) with a fluorenylmethyloxycarbonyl (Fmoc-) protecting group at the amino end are used as raw materials, the carboxyl group of Fmoc-Gly-OH is connected to 2-chlorotrityl chloride resin (2-CTC) by a covalent bond, and dimethylformamide (DMF) containing 20% (v / v) piperidine is added, and the amino protection Fmoc is removed by reaction for 0.5h. Acetyl anhydride is added to the resin to acetylate the N-terminal amino acid. At the same time, an excess of Fmoc-Cys(Trt)-OH was added, and hydroxybenzotriazole was used as a condensation agent. The reaction was carried out at 30°C for 2 hours to allow the carboxyl group on Fmoc-Cys(Trt)-OH to condense with the active amino group of Gly on the resin. The amino group deprotection and condensation reactions were repeated, and the remaining amino acids were connected in sequence. The pentapeptide was cleaved from the resin, separated and purified by a C18 column, and freeze-dried to obtain a pentapeptide (purity>90%).
[0045] Example 2 Anti-inflammatory effect test of Ac-WDDCG monomer peptide
[0046] The acetylated pentapeptide (Ac-WDDCG) synthesized by chemical method in Example 1 was subjected to cytotoxicity test and anti-inflammatory effect test.
[0047] Cytotoxicity test method: RAW264.7 cells in the logarithmic growth phase after 3 generations of recovery were inoculated in a 96-well plate to a cell concentration of 1×10 4 / well, and culture overnight for 24 hours.
[0048] Administration: The test substance was set at 4 concentration gradients and diluted with complete culture medium. Three replicate wells were set for each concentration gradient and incubated in a 37°C, 5% CO2 incubator for 24 h.
[0049] Cell activity detection: remove the original supernatant, prepare CCK-8 test solution at a ratio of complete culture medium / CCK-8 = 10 / 1, add 100 μL to each well, incubate in a 37°C, 5% CO2 incubator for 2 h, and measure the absorbance at 450 nm using an enzyme-labeled instrument.
[0050] The results are as follows Figure 1The figure shows the cytotoxicity test of WDDC and Ac-WDDCG monomer peptides at different concentrations (10-200 μg / mL) on RAW264.7. It was found that there was no cytotoxicity at 10-200 μg / mL, and the subsequent efficacy experiments all used a peptide concentration of 100 μg / mL.
[0051] Anti-inflammatory effect test method: RAW264.7 cells in the logarithmic growth phase after 3 generations of recovery were prepared with complete culture medium to 1×10 5 The cell suspension of 100 μL / well was inoculated into a 24-well plate at a rate of 500 μL per well and incubated in a 37° C., 5% CO 2 incubator for 24 h.
[0052] Drug administration and LPS: blank control group, induced stimulation group, positive control group and sample group were set up. Complete medium was added to each well of blank control group, 5 μg / mL dexamethasone (DEX) diluted with complete medium was added to each well of positive control group, and the corresponding concentration of test substance (concentration of 100 μg / mL) diluted with complete medium was added to each well of sample group. Three duplicate wells were set up for each group and incubated in a 37°C, 5% CO2 incubator for 2 hours. Except for the blank control group, a final concentration of 1 μg / mL LPS was added to each well and incubated in a 37°C, 5% CO2 incubator for 24 hours. Cell supernatant inflammatory factor detection: Cell supernatant was collected by centrifugation at 4°C, 1000g, 10 minutes in a low-temperature centrifuge, and the detection was carried out according to the instructions of ELISA kit and NO detection kit. The contents of TNF-α, IL-6 and NO in the collected cell supernatant were detected respectively, and the experimental results were analyzed by data processing software.
[0053] The results are as follows Figure 2 As shown, compared with the control group (BC group), # indicates p<0.05, ## indicates p<0.01, and ### indicates p<0.001. Compared with the model group (LPS group), * indicates p<0.05, ** indicates p<0.05, and *** indicates p<0.001. The inhibition rates of DEX on NO, TNF-α and IL-6 were 17.7%, 50.8% and 44.6%, respectively, and the average inhibition rate was 37.7%. The inhibition rates of WDDC monomer peptide on NO, TNF-α and IL-6 were 12.8%, 21.8% and 42.0%, respectively, and the average inhibition rate was 25.5%; the inhibition rates of Ac-WDDCG monomer peptide on NO, TNF-α and IL-6 were 8.4%, 37.2% and 48.5%, respectively, and the average inhibition rate was 31.4%. Comparison of average inhibition rates: Ac-WDDCG>WDDC. Therefore, both WDDC and Ac-WDDCG monomer peptides have significant anti-inflammatory effects. It also indicates that increasing glycine and acetylation does not reduce its anti-inflammatory activity.
[0054] Example 3 Stability test of Ac-WDDCG monomer peptide
[0055] Agilent 1290 high performance liquid chromatograph was used, the column was ZORBAX SB-Aq (3.0mm*100mm 3.5μM), the column temperature was 30℃, and the flow rate was 0.4mL / min. The mobile phase was 0.1% trifluoroacetic acid in acetonitrile, and the aqueous phase was 0.1% trifluoroacetic acid in water. The detection wavelength was 220nm, and the injection volume was 5μL. The peptide freeze-dried powder was dissolved in 40% 1,3-butanediol solution at a concentration of 1mg / mL and placed in a 5mL stoppered colorimetric tube for HPLC analysis.
[0056] The results are shown in Figure 3. Figure 3A and Figure 3B The HPLC spectra of WDDC on day 0 and day 30 respectively, the RSD value of the 30-day stability of WDDC monomer peptide in liquid state (40% 1,3-butanediol solution) was calculated to be 31.3%, indicating poor stability. Figure 3C and Figure 3D The HPLC spectra of Ac-WDDCG monomer peptide (dissolved in 40% 1,3-butanediol) on day 0 and day 30 respectively. The RSD value of the 30-day stability of Ac-WDDCG monomer peptide was calculated to be 7.8%, that is, the stability of Ac-WDDCG in the liquid state has been greatly improved.
[0057] Example 4 Effects of Ac-WDDCG Monomer Peptide on NLRP3 and NF-κB Signaling Pathways
[0058] The qRT-PCR method was used to test the changes in the expression levels of TLR4, NLRP3 and NF-κB factors of Ac-WDDCG monomer peptide in the HUVEC oxidative stress model.
[0059] Test method: 1.5×10 5 HUVEC cells / well were inoculated in a 6-well plate and cultured overnight for 24 hours. Then 600μM H2O2 was added for stimulation for 16 hours. At the same time, the corresponding concentration of the test substance (concentration of 100μg / mL) diluted with complete culture medium was added to each well of the sample group, and 3 replicates were set up for each group. Co-culture for 16 hours. The culture medium was aspirated, washed once with PBS, digested with trypsin, resuspended and centrifuged in DMEM, washed once with PBS, discarded the supernatant, and transferred to a 1.5mL EP tube. Used for RT-PCR detection of TLR4, NLRP3 and NF-κB factors.
[0060] The results are as follows Figure 4As shown, compared with the control group (BC group), # indicates p<0.05, ## indicates p<0.01, and ### indicates p<0.001; compared with the model group (H2O2 group), * indicates p<0.05, ** indicates p<0.01, and *** indicates p<0.001.
[0061] Ac-WDDCG monomer peptides can significantly reduce the expression of TLR4, NLRP3 and NF-κB, with inhibition rates of 29.5%, 43.7% and 27.9%, respectively. Therefore, the anti-inflammatory effect of Ac-WDDCG may be related to the inhibition of the activation of NLRP3 and NF-κB signaling pathways.
[0062] Example 5 Determination of the Effect of Ac-WDDCG Monomer Peptide on Zebrafish Neutrophil Migration
[0063] CuSO4 was used to damage the zebrafish neuromast terminal organs and induce inflammatory response to form a zebrafish inflammation model. The in vivo anti-inflammatory activity of Ac-WDDCG monomer peptide was evaluated by counting the number of inflammatory cells in the test line.
[0064] Test method: The zebrafish breeding method was carried out according to "The zebrafish book". The water temperature was maintained at about 28.5℃, with 14h of light and 10h of darkness per day, and feeding once in the morning and evening. One female and two male fish were placed in the spawning tank the night before embryo collection, and the embryos were collected the next morning. On the day of embryo collection, about 7-8hpf (hour post-fertilization), embryos in poor condition were removed, fresh egg water was replaced, and continued to be cultured in a 28.5℃ incubator. The 72hpf zebrafish with consistent development were randomly divided into 4 groups, 15 in each group, namely the normal control group, the model control group, the positive control group and the sample group. The normal control group did not ingest CuSO4, and the model control group, the positive control group and the sample group all ingested CuSO4 (CuSO4 was ingested into the zebrafish by dissolving it in the fish farming water, and the concentration of CuSO4 in the water was 1μM). The positive control group and the sample group ingested 5μg / mL DEX and 0.5mg / mL Ac-WDDCG before ingesting CuSO4. After 2 hours of incubation in the dark, samples were randomly selected from zebrafish with normal phenotype and behavior, anesthetized with tricaine, and fixed with 3% methylcellulose. Then, the samples were observed and photographed under stereofluorescence. All zebrafish photos were taken at the same time and under the same environmental conditions, and the body position of the zebrafish should be consistent. Image Pro Plus 6.0 software was used to analyze the fluorescence intensity of individual zebrafish larvae to quantify neutrophil recruitment.
[0065] Depend on Figure 5A and 5BIt can be seen that compared with the blank group, the number of neutrophils in zebrafish (model group) treated with CuSO4 increased significantly (P<0.001), indicating that CuSO4 can cause inflammatory response in zebrafish. Compared with the CuSO4 group, Ac-WDDCG monomer peptide significantly reduced CuSO4-induced zebrafish neutrophil aggregation (inhibition rate was 26.48%, P<0.01). Therefore, Ac-WDDCG monomer peptide can effectively inhibit the phenomenon of zebrafish neutrophil aggregation caused by CuSO4, and has certain anti-inflammatory activity in vivo.
[0066] Example 6 Evaluation of the anti-inflammatory activity of Ac-WDDCG monomer peptide composition
[0067] Ac-WDDCG monomer peptide was compounded with lotus seed extract and Schisandra chinensis extract to test the anti-inflammatory activity of the composition.
[0068] Group 1: by mass, including 1 part of Ac-WDDCG, 1 part of lotus seed extract, and 1 part of Schisandra chinensis extract
[0069] Group 2: by mass, including 2 parts of Ac-WDDCG, 2 parts of lotus seed extract, and 1 part of Schisandra chinensis extract
[0070] Group 3: by weight, including 1 part of Ac-WDDCG, 1 part of lotus seed extract, and 2 parts of Schisandra chinensis extract
[0071] Group 4: 1.5 parts of lotus seed extract and 1.5 parts of Schisandra chinensis extract by weight
[0072] Group 5: by weight, including 1.5 parts of Ac-WDDCG and 1.5 parts of lotus seed extract
[0073] Group 6: by weight, including 1.5 parts of Ac-WDDCG and 1.5 parts of Schisandra chinensis extract
[0074] The test methods for NO, TNF-α, and IL-6 refer to Example 2. The average inhibition rate is calculated as the average of the inhibition rates of the three inflammatory factors. The inhibition rate calculation method is as follows:
[0075] Calculation formula:
[0076] Inhibition rate (%IR) = (BA) / B × 100%
[0077] Where:
[0078] A: Sample group absorbance measurement
[0079] B: Absorbance measurement of LPS group
[0080] The inhibition rate results are shown in Table 1.
[0081] Table 1
[0082] NO(%) TNF-α(%) IL-6 (%) Average inhibition rate (%) 1 group 23.8 51.9 48.3 41.3 2 groups 22.1 47.8 46.1 38.7 3 groups 19.5 43.7 44.9 36.0 4 groups 14.7 32.6 35.2 27.5 5 groups 11.6 27.2 33.6 24.1 6 groups 15.2 21.5 28.3 21.7
[0083] From the data in Table 1, we can see that the average inhibition rate is group 1>group 2>group 3>group 4>group 5>group 6. When lotus seed and schisandra chinensis extracts were added at the same time (groups 1 / 2 / 3), the anti-inflammatory effect was better than that of the group lacking one of them (groups 4 / 5 / 6). That is, when Ac-WDDCG is combined with two plant extracts at the same time, it can play a synergistic role and achieve a better anti-inflammatory effect.
[0084] The applicant declares that the present invention illustrates an acetylated pentapeptide with anti-inflammatory effect and its application through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
[0085] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
[0086] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. An acetylated pentapeptide having anti-inflammatory effect, characterized in that: The amino acid sequence of the acetylated pentapeptide with anti-inflammatory effect includes the sequence shown in SEQ ID No. 1, and the N-terminus of the amino acid sequence is acetylated.
2. The acetylated pentapeptide with anti-inflammatory effect according to claim 1, characterized in that The acetylated pentapeptide with anti-inflammatory effect is prepared by solid phase synthesis.
3. A composition having an anti-inflammatory effect, characterized in that: The composition comprises the acetylated pentapeptide with anti-inflammatory effect as claimed in claim 1, lotus seed extract and schisandra chinensis extract.
4. The composition with anti-inflammatory effect according to claim 3, characterized in that The composition comprises, by mass, 1-2 parts of the acetylated pentapeptide with anti-inflammatory effect according to claim 1, 1-2 parts of lotus seed extract and 1-2 parts of schisandra chinensis extract.
5. Use of the acetylated pentapeptide with anti-inflammatory effect according to claim 1 or 2 or the composition with anti-inflammatory effect according to claim 3 or 4 in the preparation of a product with anti-inflammatory effect.
6. The use according to claim 5, characterized in that: The acetylated pentapeptide with anti-inflammatory effect is added in an amount of 0.01-10% in the product with anti-inflammatory effect.
7. The use according to claim 5, characterized in that: The composition with anti-inflammatory effect is added in an amount of 0.01-15% in the product with anti-inflammatory effect.
8. Use of the acetylated pentapeptide with anti-inflammatory effect according to claim 1 or 2 or the composition with anti-inflammatory effect according to claim 3 or 4 in the preparation of an inflammatory factor inhibitor.
9. Use of the acetylated pentapeptide with anti-inflammatory effect according to claim 1 or 2 in the preparation of an inhibitor of NF-κB signaling pathway.
10. Use of the acetylated pentapeptide with anti-inflammatory effect according to claim 1 or 2 in the preparation of an inhibitor of NLRP3 signaling pathway.